Association of epidermal growth factor receptor (EGFR) gene copy number amplification with neck lymph node metastasis in areca-associated oral carcinomas

被引:48
作者
Chiang, Wei-Fan [1 ,2 ,3 ]
Liu, Shyun-Yeu [3 ]
Yen, Ching-Yu [3 ]
Lin, Chin-Nan [4 ]
Chen, Yen-Chia [5 ,6 ]
Lin, Shu-Chun [1 ]
Chang, Kuo-Wei [1 ]
机构
[1] Natl Yang Ming Univ, Sch Dent, Inst Oral Biol, Taipei 112, Taiwan
[2] Chi Mei Hosp, Dept Oral & Maxillofacial Surg, Tainan, Taiwan
[3] Chi Mei Med Ctr, Dept Oral & Maxillofacial Surg, Tainan, Taiwan
[4] Chi Mei Med Ctr, Dept Pathol, Tainan, Taiwan
[5] Taipei Vet Gen Hosp, Dept Emergency Med, Taipei, Taiwan
[6] Natl Yang Ming Univ, Inst Emergency & Crit Care Med, Taipei 112, Taiwan
关键词
amplification; EGFR; oral cancer;
D O I
10.1016/j.oraloncology.2007.02.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Epidermal growth factor receptor (EGFR) has an important role in cell proliferation, differentiation, and transformation. Several alterations and activation of EGFR have been identified in tumors. Inhibitors that impair EGFR activity have been identified and studied for cancer therapy, so the present study was conducted to comprehensively assess the amplification, mutation, and expression of EGFR in areca-associated oral squamous cell carcinoma (OSCC), which might be beneficial for targeting therapy. Gene copy number amplifications of EGFR were identified in 33% (14/42) cases of OSCC. Six cases of OSCC had a high copy number amplification. Direct sequencing of PCR products of 20 representative cases of OSCC revealed no somatic mutation in the kinase domains of EGFR. Sixty-seven percent (28/42) of the OSCC cases had nuclear and/or cytosolic EGFR immunoreactivity. Significant increases in EGFR copy number and EGFR immunoreactivity were found in OSCC subjects compared with long-term areca chewers, or compared with match adjacent oral mucosa (P < 0.0001 and P= 0.029, respectively). Interestingly, OSCC with nodal involvement had significantly higher EGFR gene copy number than OSCC without nodal involvement (3.194 +/- 0.740 versus 1.733 +/- 0.246; P = 0.050). Our data suggest that genomic amplification could be a genetic basis underlying activation of the EGFR pathway in areca-associated OSCC. (c) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:270 / 276
页数:7
相关论文
共 27 条
[1]   Genome-wide profiling of oral squamous cell carcinoma [J].
Chen, YJ ;
Lin, SC ;
Kao, T ;
Chang, CS ;
Hong, PS ;
Shieh, TM ;
Chang, KW .
JOURNAL OF PATHOLOGY, 2004, 204 (03) :326-332
[2]   Up-regulation of a serine-threonine kinase protooncogene Pim-1 in oral squamous cell carcinoma [J].
Chiang, W. -F. ;
Yen, C. -Y. ;
Lin, C. -N. ;
Liaw, G. -A. ;
Chiu, C. -T. ;
Hsia, Y. -J. ;
Liu, S. -Y. .
INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2006, 35 (08) :740-745
[3]   Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas [J].
Chung, Christine H. ;
Ely, Kim ;
McGavran, Loris ;
Varella-Garcia, Marileila ;
Parker, Joel ;
Parker, Natalie ;
Jarrett, Carolyn ;
Carter, Jesse ;
Murphy, Barbara A. ;
Netterville, James ;
Burkey, Brian B. ;
Sinard, Robert ;
Cmelak, Anthony ;
Levy, Shawn ;
Yarbrough, Wendell G. ;
Slebos, Robbert J. C. ;
Hirsch, Fred R. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (25) :4170-4176
[4]   Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck [J].
Cohen, EEW ;
Rosen, F ;
Stadler, WM ;
Recant, W ;
Stenson, K ;
Huo, DZ ;
Vokes, EE .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (10) :1980-1987
[5]   Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR [J].
Cohen, EEW ;
Lingen, MW ;
Martin, LE ;
Harris, PL ;
Brannigan, BW ;
Haserlat, SM ;
Okimoto, RA ;
Sgroi, DC ;
Dahiya, S ;
Muir, B ;
Clark, JR ;
Rocco, JW ;
Vokes, EE ;
Haber, DA ;
Bell, DW .
CLINICAL CANCER RESEARCH, 2005, 11 (22) :8105-8108
[6]   A chromosomal region 7p11.2 transcript map: Its development and application to the study of EGFR amplicons in glioblastoma [J].
Eley, GD ;
Reiter, JL ;
Pandita, A ;
Park, S ;
Jenkins, RB ;
Maihle, NJ ;
James, CD .
NEURO-ONCOLOGY, 2002, 4 (02) :86-94
[7]   Signaling via ErbB2 and ErbB3 associates with resistance and Epidermal Growth Factor Receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells [J].
Erjala, Kaisa ;
Sundvall, Maria ;
Junttila, Teemu T. ;
Zhang, Na ;
Savisalo, Mika ;
Mali, Pekka ;
Kulmaia, Jarmo ;
Pulkkinen, Jaakko ;
Grenman, Reidar ;
Elenius, Klaus .
CLINICAL CANCER RESEARCH, 2006, 12 (13) :4103-4111
[8]   EGFR inhibitors: what have we learned from the treatment of lung cancer? [J].
Giaccone, G ;
Rodriguez, JA .
NATURE CLINICAL PRACTICE ONCOLOGY, 2005, 2 (11) :554-561
[9]   Clinical potential of inhibitors of survival pathways and activators of apoptotic pathways in treatment of cervical cancer: changing the apoptotic balance [J].
Hougardy, BM ;
Maduro, JH ;
van der Zee, AGJ ;
Willemse, PHB ;
de Jong, S ;
de Vries, EGE .
LANCET ONCOLOGY, 2005, 6 (08) :589-598
[10]   High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan [J].
Huang, SF ;
Liu, HP ;
Li, LH ;
Ku, YC ;
Fu, YN ;
Tsai, HY ;
Chen, YT ;
Lin, YF ;
Chang, WC ;
Kuo, HP ;
Wu, YC ;
Chen, YR ;
Tsai, SF .
CLINICAL CANCER RESEARCH, 2004, 10 (24) :8195-8203